This update outlines data from a preplanned analysis of the pivotal E4599 study in patients with non-small cell lung cancer (NSCLC), published in the Journal of Thoracic Oncology. The analysis looked at the impact of treatment with Avastin? (bevacizumab) in combination with paclitaxel/carboplatin chemotherapy, according to histology subgroup of NSCLC. Outstanding survival benefits: - The results demonstrate that first line Avastin-based therapy provided the longest median overall survival (OS)